The Juno Board of Directors is comprised of industry leaders with an outstanding track record of navigating novel science and building enduring companies.
Hal Barron is President, Research and Development at Calico, a Google-back biotechnology company focused on the aging process.
CEO & President
Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our board of directors since September 2013.
Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our Board of Directors since September 2013. Mr. Bishop has also served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, since May 2012. Mr. Bishop previously served as Chairman of the Board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012. From February 2012 until October 2012, Mr. Bishop was the Chief Operating Officer of PhotoThera, Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Mr. Bishop previously served as Executive Vice President and Chief Operating Officer at Dendreon Corporation, a cancer cell therapy company, from January 2010 to September 2011.
Mr. Bishop has also served as the President of the Specialty Medicine Business at Bayer Healthcare Pharmaceuticals, Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology, and hematology products. Mr. Bishop was employed by Chiron Corporation as Senior Vice President of Global Commercial Operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London.
Thomas Daniel is Chairman of Celgene Research at Celgene Corporation.
Thomas O. Daniel has been Chairman of Celgene Research at Celgene Corporation since January 2016. Dr. Daniel was previously Celgene’s President of Research and Early Development from December 2006 to January 2016 and served as Celgene Corporation’s Executive Vice President and President of Research and Early Development from February 2012 until July 2014. Prior to joining Celgene, Dr. Daniel served as the Chief Scientific Officer and director at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to Ambrx, Dr. Daniel served as Vice President of Research at Amgen Inc., where he was research site head of Amgen Washington and therapeutic area head of inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex. Dr. Daniel is a member of the therapeutic advisory board of aTyr Pharma, Inc. and is a director of FerruMax Pharmaceuticals and PharmAkea Therapeutics, privately-held biotechnology companies. Dr. Daniel was also formerly a director of Epizyme, Inc. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and the Biomedical Advisory Council of PhRMA. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel received a B.A. from the Southern Methodist University in Texas in 1974 and an M.D. from the University of Texas, Southwestern, in 1978, and completed medical residency at Massachusetts General Hospital.
Anthony Evnin is a Partner of Venrock with significant experience as a director of many other biotechnology companies.
Director & Co-Founder
Dr. Klausner is founder and Director of GRAIL and Executive Chairman of Wisdo, a third generation internet company.
Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for U.S. Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Director & Co-Founder
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Kythera Biopharmaceuticals, Sapphire Energy, Sage Therapeutics, Ensemble Therapeutics, Syros Pharmaceuticals, NextCODE Health, and serves as Chairman of Hua Medicine. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Chairman & Director
Howard Pien has worked in the pharmaceutical and biotechnology industries for over 30 years.
Maggie Wilderotter has served as a member of our board of directors since November 2014.
Maggie Wilderotter was Chief Executive Officer of Frontier Communications from November, 2004 to April, 2015, and then Executive Chairman of the company until April, 2016. During her tenure with Frontier, the company grew from a regional telephone company with customer revenues of less than $1 billion to a national broadband, voice and video provider with operations in 29 states and annualized revenues in excess of $10 billion.
Previously, Mrs. Wilderotter was Senior Vice President of Global Business Strategy and ran the Worldwide Public Sector at Microsoft. Before this, she was President and CEO of Wink Communications Inc., Executive Vice President of National Operations for AT&T Wireless Services Inc., Chief Executive Officer of AT&T’s Aviation Communications Division, and a Senior Vice President of McCaw Cellular Communications Inc.
Mrs. Wilderotter serves on the boards of Costco Wholesale Corporation, Hewlett Packard Enterprise, and Juno Therapeutics, Inc. as well as a number of private and non-profit organizations. Mrs. Wilderotter is also a Senior Advisor to the Blackstone Group.
Mrs. Wilderotter previously served on the President’s National Security Telecommunications Advisory Committee (NSTAC) as both Vice Chairman and Chairman during her 4-year tenure ending in 2014. Mrs. Wilderotter also served until January, 2017 on the President’s special Commission responsible for a recommendation report to the new President of the United States on Enhancing National Cybersecurity.
Mrs. Wilderotter is a member of the Board of Directors of The Conference Board; a member of the Executive Committee of the Catalyst Board of Directors; a member of the Board of Women in America; and a member of the Business Council, WPO; Women Corporate Directors (WCD) and the Committee of 200.
Mrs. Wilderotter holds a bachelor’s degree in economics from the College of the Holy Cross. She has been awarded an Honorary Doctor of Engineering degree from the Stevens Institute of Technology and an Honorary Doctor of Laws degree from the University of Rochester.
Rupert Vessey is EVP and President, Research and Early Development at Celgene.
Rupert Vessey, MA, BM BCh, FRCP, DPhil, joined Celgene in January 2015 as Senior Vice President, Translational Development. Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics. Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases. Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM, BCH) and a DPhil (PhD) in Molecular Immunology. He is an elected Fellow of the Royal College of Physicians.